Bausch Health takes option to buy all ophthalmology assets of Allegro

Canada’s Bausch Health (TSX: BHC) has entered into an agreement to acquire an option to purchase all ophthalmology assets of USA-based Allegro Ophthalmics, including global rights for Luminate (risuteganib), Allegro's lead investigational compound in retina, which is believed to simultaneously act on the angiogenic, inflammatory and mitochondrial metabolic pathways implicated in diseases such as intermediate dry age-related macular degeneration (AMD).